Adma Biologics (ADMA) EBITDA (2011 - 2025)

Adma Biologics' EBITDA history runs 13 years deep, the most recent figure standing at $62.8 million for Q4 2025.

• Quarterly EBITDA rose 63.74% year-over-year to $62.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $191.4 million (up 37.74% YoY) and the FY2025 annual result came in at $191.4 million, up 37.75% from the prior year.
• EBITDA was $62.8 million for Q4 2025 at Adma Biologics, up from $51.0 million in the prior quarter.
• Across five years, EBITDA topped out at $62.8 million in Q4 2025 and bottomed at -$15.6 million in Q2 2021.
• A 5-year average of $12.7 million and a median of $4.1 million in 2023 frame the typical range for EBITDA.
• Annual changes were most pronounced in 2021 — EBITDA fell 4.61% — and 2024, when it surged 8387.74%.
• Adma Biologics' EBITDA stood at -$13.2 million in 2021, then surged by 54.07% to -$6.1 million in 2022, then jumped by 334.93% to $14.2 million in 2023, then soared by 169.25% to $38.3 million in 2024, then soared by 63.74% to $62.8 million in 2025.
• Business Quant data shows ADMA's EBITDA at $62.8 million in Q4 2025, $51.0 million in Q3 2025, and $42.8 million in Q2 2025.